In the journey to outperform the market, investors delve into the art of stock selection. Choosing the right stocks can be a powerful driver for wealth accumulation.
After finishing at $9.07 in the prior trading day, Gyre Therapeutics Inc (NASDAQ: GYRE) closed at $7.68, down -15.33%. In other words, the price has decreased by -$15.33 from its previous closing price. On the day, 0.61 million shares were traded.
Ratios:
Our goal is to gain a better understanding of GYRE by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 3.19 and its Current Ratio is at 3.60. In the meantime, Its Debt-to-Equity ratio is 0.02 whereas as Long-Term Debt/Eq ratio is at 0.01.
On February 10, 2021, Piper Sandler started tracking the stock assigning a Overweight rating and target price of $15.Piper Sandler initiated its Overweight rating on February 10, 2021, with a $15 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on May 27 ’25 when Ma Songjiang sold 2,000 shares for $10.28 per share. The transaction valued at 20,560 led to the insider holds 2,806,642 shares of the business.
Ma Songjiang sold 558 shares of GYRE for $5,619 on May 28 ’25. The President now owns 2,806,084 shares after completing the transaction at $10.07 per share. On May 22 ’25, another insider, Ma Songjiang, who serves as the President of the company, sold 2,000 shares for $10.97 each. As a result, the insider received 21,940 and left with 2,808,824 shares of the company.
Valuation Measures:
As of this moment, Gyre’s Price-to-Earnings (P/E) ratio for their current fiscal year is 160.33, and their Forward P/E ratio for the next fiscal year is 6.56. For the stock, the TTM Price-to-Sale (P/S) ratio is 6.89 while its Price-to-Book (P/B) ratio in mrq is 9.88.
Stock Price History:
Over the past 52 weeks, GYRE has reached a high of $19.00, while it has fallen to a 52-week low of $6.11. The 50-Day Moving Average of the stock is -14.93%, while the 200-Day Moving Average is calculated to be -32.88%.
Shares Statistics:
A total of 87.64M shares are outstanding, with a floating share count of 16.26M. Insiders hold about 81.99% of the company’s shares, while institutions hold 2.89% stake in the company.
Earnings Estimates
The consensus estimate for the next quarter is $0, with high estimates of $0 and low estimates of $0.
Analysts are recommending an EPS of between $0 and $0 for the fiscal current year, implying an average EPS of $0.
Revenue Estimates
For the next quarter, 1 analysts are estimating revenue of $34.3M. There is a high estimate of $34.3M for the next quarter, whereas the lowest estimate is $34.3M.
A total of 1 analysts have provided revenue estimates for GYRE’s current fiscal year. The highest revenue estimate was $125.5M, while the lowest revenue estimate was $125.5M, resulting in an average revenue estimate of $125.5M. In the same quarter a year ago, actual revenue was $105.76M
